Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HRS9531-301 (GEMINI-1, NCT06396429)

HRS9531-301 (GEMINI-1, NCT06396429)

Ribupatide (HRS9531) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
obesity
Official title
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
3
Registry status
completed · 2024-05 → 2025-07
Participants
567
Duration
48 weeks
Registry
NCT06396429

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
2 mgobesity china48567−11.2 % vs −1.4 %
Δ −9.8 pp
−10.7 % vs −1.4 %
Δ −9.3 pp
—0.7 vs 0.0—16.2 vs 4.914.1 vs 2.11.4 vs 5.6—press release
4 mgobesity china48567−17.4 % vs −1.4 %
Δ −16.0 pp
−16.4 % vs −1.4 %
Δ −15.0 pp
—0.7 vs 0.0—17.0 vs 4.919.1 vs 2.15.0 vs 5.6—press release
6 mgobesity china48567−19.2 % vs −1.4 %
Δ −17.8 pp
−17.7 % vs −1.4 %
Δ −16.3 pp
—1.4 vs 0.0—27.0 vs 4.924.1 vs 2.14.3 vs 5.6—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (18)
  • 2 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 2 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 2 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 2 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 2 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 2 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
  • 4 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 4 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 4 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 4 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 4 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 4 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
  • 6 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 6 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 6 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 6 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 6 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 6 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS9531-301 (GEMINI-1, NCT06396429). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-301/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.